| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 1.0K | 16.7% | 12.1% |
| Total Income | 1.0K | 16.4% | 11.9% |
| Expenditure | 978.36 | 16.8% | 11.3% |
| PBT | 50.89 | 8.7% | 24.3% |
| Net Profit | 37.76 | 6.6% | 17.0% |
| OPM | 9.98% | 0.67pp | 1.00pp |
| NPM | 3.67% | 0.33pp | 0.16pp |
| EPS | 2.79 | 6.5% | 16.7% |
Detailed report is being prepared.
Can Pennar Accelerate PAT Growth to 20% as Mix Improves?
Q1 FY27 showed margin expansion but PAT growth lagged full-year guidance. Q2 will test whether the company's push into high-margin PEB and Raebareli plant ramp can deliver the 20% profit growth target.
The Setup: PAT Growth Must Accelerate
Pennar Industries started FY27 with a mixed signal: strong margin expansion in Q1 (EBITDA margin 10.65%, up from base), yet PAT growth of only 10.79% YoY — halfway to the company's 20% full-year guidance. The company's strategy centers on transitioning to higher-margin engineered products (PEB India and PEB U.S.) and the Raebareli plant coming online (30% capacity uplift), both of which should improve profitability and cash generation. Q2 results will test whether this mix-driven earnings story is translating into actual execution.
~₹880–900 Cr
Q1 was ₹884.55 Cr (+3.58% YoY); company guided for 9% single-digit growth, with double-digit in key segments
~15–20% YoY
To hit full-year 20%, Q2–Q4 must accelerate past Q1's 10.8%; every basis point of margin helps
~11–12%
Q1 at 10.65%; further expansion signals mix shift and Raebareli scaling materializing
What a strong print looks like: Q2 revenue in the ₹900–920 Cr range with PAT growth at 15%+ YoY, backed by visible EBITDA margin expansion to 11.5%+ and segment granularity showing PEB India/U.S. momentum. Signs of Raebareli plant moving from capex phase to production ramp. What weak looks like: Revenue flat or down YoY, PAT growth stalling below 8–10%, EBITDA margin contracting. Any disclosure of Raebareli delays or slower PEB U.S. uptake would flag execution risk and push out the margin uplift timeline.
On Track for the Year?
FY26 was a breakout: ₹3,666.32 Cr revenue (+14% YoY), ₹401.32 Cr EBITDA, PAT growth of 16.22%. In FY27, the company is moderating to 9% revenue growth while targeting resilient 20% PAT growth — a tighter margin story. Q1's revenue growth of 3.58% signals macro headwinds or demand softness, but PAT still grew 10.8%, showing operational discipline. For the full-year thesis to hold, Q2 must show acceleration; if growth stays in single digits next quarter, the 20% PAT guide becomes a stretch.
What the Street Says
Since Q1 FY27 — What's Changed?
No major operational or financial shocks. Governance & logistics: Trading window closed Sept 25 – Oct 2 (pre-result, routine). RTA corporate office relocation effective Dec 1, 2026 (administrative, routine). Ownership dynamics: Promoter stable at 39.67%; FII declined 5 bps to 3.99%, DII rose 62 bps to 5.90% in Q1 FY27 — modest rotation but no major institutional selling. Capital: Company guaranteed ₹34 Cr for ZAP91 Solar JV (Aug 2026) — minor, no impact on core segments. Raebareli plant on track per latest disclosures.
Q2 Watch List
1 · PAT growth acceleration
Must see 15%+ YoY (or ₹40+ Cr) to remain on track for 20% full-year. Below 12% signals guidance miss.
2 · EBITDA margin trajectory
Expect 11%+; any contraction from Q1's 10.65% would flag demand/cost pressure and delay the mix story.
3 · PEB India & PEB U.S. segment updates
Granular disclosure on high-margin segment momentum; slow PEB U.S. growth would extend margin uplift timeline.
4 · Raebareli plant production status
Management commentary on commissioning timeline and capacity utilization; capex payback credibility hinges on this.
Pennar Industries is at an inflection point. Q1's soft 3.58% revenue growth against 9% guidance and 10.8% PAT growth against a 20% target leave little room for Q2 miss. The margin expansion narrative — Raebareli capacity, PEB India/U.S. mix — is compelling if executed; Street is pricing in success with a 64% upside target. Q2 will confirm whether the thesis is real.
Three things to monitor: PAT growth breaking 15%+ to show margins are actually expanding, EBITDA margin holding/improving to validate the mix story, and segment detail on PEB U.S. momentum. If Q2 delivers double-digit PAT growth and margin breadth, the 20% full-year guidance becomes credible. A flat quarter or margin contraction would trigger a re-rating lower.